260 related articles for article (PubMed ID: 35366167)
1. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.
Rivera D; Ferrajoli A
Curr Oncol Rep; 2022 Aug; 24(8):1003-1014. PubMed ID: 35366167
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
Williams AM; Baran AM; Meacham PJ; Feldman MM; Valencia HE; Newsom-Stewart C; Gupta N; Janelsins MC; Barr PM; Zent CS
Leuk Lymphoma; 2018 Mar; 59(3):625-632. PubMed ID: 28696801
[TBL] [Abstract][Full Text] [Related]
4. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia.
Tadmor T; Welslau M; Hus I
Expert Rev Hematol; 2018 Jan; 11(1):57-70. PubMed ID: 29160119
[TBL] [Abstract][Full Text] [Related]
5. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
Kojima K
Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenesis, prophylaxis and treatment of infections in patients with chronic lymphocytic leukemia].
Stelmach P; Robak T
Postepy Hig Med Dosw (Online); 2013 Jun; 67():560-8. PubMed ID: 23799400
[TBL] [Abstract][Full Text] [Related]
8. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
9. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
12. Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia.
Iskierka-Jażdżewska E; Robak T
Expert Rev Hematol; 2020 Jan; 13(1):39-53. PubMed ID: 31747803
[No Abstract] [Full Text] [Related]
13. Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections.
Diella L; Bavaro DF; Loseto G; Pasciolla C; Minoia C; Di Gennaro D; Belati A; De Candia MS; Di Gennaro F; Saracino A; Guarini A
Expert Rev Hematol; 2023 Apr; 16(4):267-276. PubMed ID: 37012253
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT; van der Straten L; van Gelder M; Kersting S; Levin MD; Mous R; van der Straaten HM; Nijziel MR; van der Spek E; Posthuma EFM; Visser HPJ; van der Klift M; de Heer K; Bellido M; Doorduijn JK; Bruns AHW; Raijmakers RAP; Kater AP;
Leuk Lymphoma; 2022 Oct; 63(10):2276-2289. PubMed ID: 35737364
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Molica S; Polliack A
Leuk Res; 2016 Nov; 50():31-36. PubMed ID: 27657651
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia.
Byrd JC; Stilgenbauer S; Flinn IW
Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
[TBL] [Abstract][Full Text] [Related]
18. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
19. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.
Teh BW; Tam CS; Handunnetti S; Worth LJ; Slavin MA
Blood Rev; 2018 Nov; 32(6):499-507. PubMed ID: 29709246
[TBL] [Abstract][Full Text] [Related]
20. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.
Randhawa JK; Ferrajoli A
Expert Rev Hematol; 2016 Mar; 9(3):235-44. PubMed ID: 26652692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
